RNS Number : 9061X
Acambis PLC
30 June 2008
Voting rights and capital
Cambridge, UK and Cambridge, Massachusetts - 30 June 2008 - Acambis plc (Acambis) (LSE:
ACM) ), in conformity with the Financial
Services Authority's ("FSA") Transparency Directive, notifies that on 30 June 2008 Acambis'
share capital consisted of 145,505,287 ordinary
10p shares, each share having equal voting rights.
This figure may be used by shareholders as the denominator for the calculations by which
they will determine if they are required to
notify their interest in, or a change to their interest in, Acambis under the FSA's Disclosure
and Transparency Rules.
-ends-
Enquiries:
Acambis plc
Ian Garland, Chief Executive Officer
Elizabeth Jones, Chief Financial Officer
Lyndsay Wright, VP, Communications and IR
Tel: +44 (0) 1223 275 300
Brunswick
Jon Coles / Justine McIlroy / Annabel Entress
Tel: +44 (0) 20 7404 5959
About Acambis
Acambis is a vaccine company developing novel vaccines that address significant unmet medical
needs or substantially improve standards of
care. It has a broad pipeline of novel vaccine candidates, including:
* the only single-dose vaccine in development against Japanese encephalitis (JE);
* the leading vaccine in development against the West Nile virus;
* a tetravalent dengue vaccine that has achieved proof-of-concept by generating 100%
seroconversion to all four dengue virus
serotypes;
* the only vaccine in development against Clostridium difficile bacteria, a leading
case of hospital-acquired infections;
* a novel influenza vaccine that provides a universal approach to tackling 'A' strains
of the virus; and
* a novel replication-deficient vaccine, dl5-29, against genital herpes.
Acambis has partnerships with sanofi pasteur for the development and commercialisation of
the JE, West Nile and dengue vaccines. These
are based on Acambis' proprietary ChimeriVax* technology, which was developed in association
with St Louis University.
Acambis is recognised internationally as the leading producer of smallpox vaccines for
emergency-use stockpiles held by the US
Government and several other governments around the world. Acambis developed its ACAM2000*
smallpox vaccine under contracts with the US
Government.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and is listed on the
London Stock Exchange (ACM). More information
is available at www.acambis.com.
"Safe Harbour" statement
Statements contained within this news release may contain forward-looking comments, which
involve risks and uncertainties that may cause
actual results to vary from those contained in the forward-looking statements. In some cases,
you can identify such forward-looking
statements by terminology such as 'may', 'will', 'could', 'forecasts', 'expects', 'plans',
'anticipates', 'believes', 'estimates',
'predicts', 'potential', or 'continue'. Predictions and forward-looking references in this
news release are subject to the satisfactory
progress of research which is, by its very nature, unpredictable. Forward projections reflect
management's best estimates based on
information available at the time of issue.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVRFMMITMMIJBTP
|